All

Vedanta Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting
24 May 2022

Vedanta Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting

Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, today announced the details...

Read more
Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies
3 May 2022

Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies

Tubulis today announced the successful completion of a €60 million (USD $63 million) Series B financing led by Andera Partners with participation from new investors Evotec...

Read more
INRAE and MaaT Pharma Build on the Success of their Long-Standing Partnership with the Entry of Drug-Candidate MaaT013 into Phase 3 Clinical Trial
21 April 2022

INRAE and MaaT Pharma Build on the Success of their Long-Standing Partnership with the Entry of Drug-Candidate MaaT013 into Phase 3 Clinical Trial

MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to...

Read the press release
BCD Bioscience, a Precision Prebiotic Fiber Company, Raises $12M In Series A Funding to Develop Lead Products
13 April 2022

BCD Bioscience, a Precision Prebiotic Fiber Company, Raises $12M In Series A Funding to Develop Lead Products

BCD Bioscience, a biotechnology company creating precision prebiotics from natural fibers, today announced that it has completed an oversubscribed Series A financing round of...

Read more
MaaT Pharma Announces First Patient Dosed in Phase 3 ‘ARES’ Trial Evaluating MaaT013 in Patients with Acute Graft-vs-Host-Disease
28 March 2022

MaaT Pharma Announces First Patient Dosed in Phase 3 ‘ARES’ Trial Evaluating MaaT013 in Patients with Acute Graft-vs-Host-Disease

A French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer,...

Read the press release
Microbiome Space in Spotlight as Microbiotica Sets Funding Record
11 March 2022

Microbiome Space in Spotlight as Microbiotica Sets Funding Record

Competition is heating up in the microbiome niche as UK-based Microbiotica raised €60M (£50M) in a Series B round to advance two candidates designed to treat cancer and...

Read more
Backing the Microbiome: The Investor Perspective
11 March 2022

Backing the Microbiome: The Investor Perspective

Life science research changes frequently, with new discoveries being published every day. Some of these discoveries form the basis of new biotech companies, but whether or not...

Read more
Microbiotica raises £50 million ($67 million) to advance pipeline of microbiome-based therapeutics
7 March 2022

Microbiotica raises £50 million ($67 million) to advance pipeline of microbiome-based therapeutics

Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and biomarkers, today announced the completion of a £50 million ($67 million) Series...

Read the press release